Why the study?
Do ET-1 and ET-2 initiate and maintain contractile responses through different mechanisms in rat mesenteric and basilar arteries?
Do ET-1 and ET-2 initiate and maintain contractile responses through different mechanisms in rat mesenteric and basilar arteries?
ET-1 and ET-2 initiate and maintain vasoconstriction through distinct mechanisms that vary by vascular bed, suggesting potential for agonist- and vascular bed-selective pharmacotherapy.
Answers are grounded in this paper and cite their sources.
Mechanistic distinctions between ET-1/ET-2 in rat arteries leave open agonist- and bed-selective targeting; human relevance untested.
BACKGROUND AND PURPOSE: Endothelin (ET)-1 and ET-2 cause potent long-lasting vasoconstrictions by tight binding to smooth muscle ETA receptors. We tested the hypotheses that different mechanisms mediate initiation and maintenance of arterial contractile responses to ET-1 and ET-2 and that this differs among vascular beds. EXPERIMENTAL APPROACH: Segments of rat mesenteric resistance artery (MRA) and basilar artery (BA) were studied in wire myographs with and without functional antagonists. KEY RESULTS: Sensitivity and maximum of MRA contractile responses to ET-1 were not, or only moderately, reduced by stimulation of soluble GC, AC or K(+) -channels and by an inhibitor of receptor-operated ion channels. However, each of these reduced maintenance of ET-1 effects and relaxed ET-1-induced contractions in MRA. A calcium channel antagonist did not alter sensitivity, maximum and maintenance of ET-1 effects, but relaxed ET-1-induced contractions in MRA. A PLC inhibitor prevented contractile responses to ET-1 and ET-2 in MRA and BA, and relaxed ET-1- and ET-2-induced responses in MRA and ET-1 effects in BA. A Rho-kinase inhibitor did not modify sensitivity, maximum and maintenance of responses to both peptides in both arteries but relaxed ET-2, but not ET-1, effects in MRA and ET-1 effects in BA. CONCLUSIONS AND IMPLICATIONS: PLC played a key role in arterial contractile responses to ETs, but ET-1 and ET-2 initiated and maintained vasoconstriction through different mechanisms, and these differed between MRA and BA. Selective functional antagonism may be considered for agonist- and vascular bed selective pharmacotherapy of ET-related diseases.
No takes yet. Share an insight, caveat, or question.
Compeer et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: